Written Description: Whats Up With That? Patent Law Sept. 9, 2004 Prof Merges.

Slides:



Advertisements
Similar presentations
PATENTS IN BIOTECHNOLOGY presented to the IEEE Engineering in Medicine and Biology Buenaventura Chapter Nicole Ballew Chang, PhD Lauren E. Schneider, Esq.
Advertisements

35 U.S.C. § 112, First Paragraph By: Sheetal S. Patel.
Disclaimer: The information provided by the USPTO is meant as an educational resource only and should not be construed as legal advice or written law.
Patent Law and Policy University of Oregon Law School Fall 2009 Elizabeth Tedesco Milesnick Patent Law and Policy, Fall 2009 Class 5, Slide 1.
Compliance with the Written Description Requirement FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza New York, NY Raymond.
Incorporation by Reference
Recent U.S. Court Decisions for Valid Priority Claims AIPLA AIPLA Mid-Winter Institute IP Practice in Japan Committee Pre-Meeting Seminar January 29-30,
EACCNJ European Union IP Forum Mark DeLuca Pepper Hamilton LLP September 27, 2012.
Written Description and Novelty Intro to IP Prof Merges –
Enablement and Written Description Intro to IP – Prof Merges Jan. 19, 2012.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
The America Invents Act (AIA) - Rules and Implications of First to File, Prior Art, and Non-obviousness -
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Claim Interpretation By: Michael A. Leonard II and Jared T. Olson.
“REACH-THROUGH CLAIMS”
Recent Developments In Patent Law: Update On Federal Circuit Cases FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza New.
Patent Processing – Examination Issues Patent, Trademark, and Copyright - Law and Policy 5-8 November 2007 Amman, Jordan Global Intellectual Property Academy.
Side 1 Andrew Chin AndrewChin.com What Metaphysics Can Tell Us About Law Steven D. Smith (2006): Do we hold outdated conceptions.
Written Description II Prof Merges Sept. 7, 2010.
Doctrine of Equivalents Intro to IP – Prof Merges
DOE/PHE II Patent Law. United States Patent 4,354,125 Stoll October 12, 1982 Magnetically coupled arrangement for a driving and a driven member.
Intellectual Property Boston College Law School February 28, 2007 Patent - Enablement.
Intellectual Property Boston College Law School February 27, 2008 Patent - Enablement.
by Eugene Li Summary of Part 3 – Chapters 8, 9, and 10
Intellectual Property
Enablement and Written Description Prof. Robert Merges
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
Written Description II Prof Merges Feb. 4, The Written Description Requirement Gentry Gallery, Inc. v. Berkline Corp., 134 F.3d 1473 (Fed. Cir.
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
SECTION 101 OF THE PATENT LAW Describes what is patentable subject matter: "Whoever invents or discovers any new and useful process, machine, manufacture,
1 35 U.S.C. § 102(e): The Legislative Fix (S.320) and Serial Abandonment of Provisional Applications Stephen G. Kunin Deputy Commissioner for Patent Examination.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
©2011 Haynes and Boone, LLP 1 Functional Language in Claims David O’Dell Haynes and Boone LLP
The Patent Document II Class Notes: January 23, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
California :: Delaware :: Florida :: New Jersey :: New York :: Pennsylvania :: Virginia :: Washington, DC :: Advice for Drafting.
Routine Optimization Jean Witz, tQAS, TC
1 LAW DIVISION PATENT DIVISION TRADEMARK & DESIGN DIVISION ACCOUNTING & AUDITING DIVISION YUASA AND HARA LAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING.
Prosecution Group Luncheon November, Prioritized Examination—37 CFR “No fault” special status under 1.102(e) Request made with filing of nonprovisional.
PatentEng-Berkeley-Lavian Week 6: Validity and Infringement 1 Patent Engineering IEOR 190G CET: Center for Entrepreneurship &Technology Week 6 Dr. Tal.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
New Sections 102 & 103 (b) Conditions for Patentability- (1) IN GENERAL- Section 102 of title 35, United States Code, is amended to read as follows: -`Sec.
Patent Prosecution May PCT- RCE Zombie 371 National Stage PCT Applications –Not Allowed to file an RCE until signed inventor oath/declaration is.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Derivation Proceedings Gene Quinn Patent Attorney IPWatchdog.com March 27 th, 2012.
Prosecution Group Luncheon Patent October PTO News Backlog of applications continues to decrease –623,000 now, decreasing about 5,000/ month –Expected.
Patents II Disclosure Requirements Class 12 Notes Law 507 | Intellectual Property | Spring 2004 Professor Wagner.
Patents and the Patenting Process Patents and the Inventor’s role in the Patenting Process.
Nuts and Bolts of Patent Law presented by: Shamita Etienne-Cummings April 5, 2016.
Functional Claiming in Chemical Applications Ricardo Moran Schwegman Lundberg & Woessner, PA May 2017.
Written Description Prof. Merges
Processes Which Employ Non-Obvious Products
Enablement and Written Description
OTHER INVALIDITY CHALLENGES
Global Innovation Management Workout on Writing a Patent
Law 677 | Patent Law | Spring 2003
Enzo Biochem, Inc. v. Gen-Probe Inc. 323 F. 3d 956 C. A. Fed. (N. Y
Patents II Disclosure Requirements
Wisdom of the Board Ex parte PTAB Decisions Show Effective Arguments to Overcome an Obviousness Rejection Trent Ostler The content is exclusively the.
Update and Practical Considerations
Chapter 4: Patents and Trade Secrets in the Information Age.
Examination Issues: Immunology
Presentation transcript:

Written Description: Whats Up With That? Patent Law Sept. 9, 2004 Prof Merges

The Written Description Requirement Scope of enablement vs. scope of that which you have described Gentry Gallery, Inc. v. Berkline Corp., 134 F.3d 1473 (Fed. Cir. 1998). Gentry was granted a patent for a sectional sofa comprised of a pair of reclining seats that faced the same direction. Claim 1, the broadest claim, identifies a fixed console between the pair of seats. Claims 9, 10, 12-15, and are directed to a sectional sofa in which the control means are specifically located on the console. The term console does not cover a sofa section having a seat back that folds down to serve as a table top. (This was to distinguish Gentrys sofa from prior art.) The Federal Circuit limits the scope of the claim to cover sofas in which the recliner control is located on the console and invalidates 12 claims in the patent under § 112. The court affirmed that Berkline had not infringed on Gentrys patent by constructing reclining chairs separated by a center seat whose back cushion pivoted to form a table. Original Claim Language: Prosecution History: Amended Claim Language:

Gentry Gallery, contd Canon 1: Claims should be interpreted such that the preferred embodiment falls within their scope. Gentry Gallery, Inc. v. Berkline Corp., 134 F.3d 1473 (Fed. Cir. 1998). Gentry was granted a patent for a sectional sofa comprised of a pair of reclining seats that faced the same direction. Claim 1, the broadest claim, identifies a fixed console between the pair of seats. Claims 9, 10, 12-15, and are directed to a sectional sofa in which the control means are specifically located on the console. The term console does not cover a sofa section having a seat back that folds down to serve as a table top. (This was to distinguish Gentrys sofa from prior art.) The Federal Circuit limits the scope of the claim to cover sofas in which the recliner control is located on the console and invalidates 12 claims in the patent under § 112. The court affirmed that Berkline had not infringed on Gentrys patent by constructing reclining chairs separated by a center seat whose back cushion pivoted to form a table. Original Claim Language: Prosecution History: Amended Claim Language:

Patent Specification Enabled Described Claim 1 Original Application Enabled subject matter: everything the inventor teaches to one of skill in the art. Described embodiments of the invention: everything the inventor adequately describes to one in the art; everything the inventor shows she is in possession of or contemplates as embraced by her invention Claim 2 Claimed in C-I-P or amended application Specification

Specification Re-filed Enabled Described Claim 1 Original Application If the inventor re-files the specification at a later date, she cannot claim what the first filing enabled but failed to describe. Enabled Described Claim 2

Whats claimable? Dedicated to the Public Original Description Taught by Patent Claimable by original inventor Competitor

Gentry Gallery v. Berkline Corp. Enabled Described Claim 1 Specification for Gentry patent Enabled: 2 reclining seats in a sectional sofa; controls not located on arms of chair Described: pair of reclining seats in a sectional sofa with a fixed console that houses the control means Claimed: pair of reclining seats in a sectional sofa, a fixed console, and a pair of controls.

In re Curtis, 69 USPQ2d 1274 (CA FC 2004) 69 USPQ2D 1274 In re Curtis U.S. Court of Appeals Federal Circuit No Decided January 6, 2004

In re Curtis, contd The Board determined that Curtis could not traverse the examiners rejections by claiming the benefit of an earlier patent application because the disclosure therein failed to adequately describe the subject matter encompassed by the rejected claims under 35 U.S.C. §112, ¶ 1. Because the Boards decision is supported by substantial evidence and otherwise is in accordance with law, we affirm.

Univ of Rochester v. Searle Univ. of Rochester v. GD Searle & Co., 358 F.3d 916 (Fed. Cir. 2004) – business as usual in the application of the written description Requirement

Patent for a method of treating inflammation using inhibitors of prostaglandin H synthase-2 (PGHS-2) enzyme activity, also known as COX-2

Claimed method of using a compound acting upon a polypeptide did not comply with the written description requirement where such a compound was not disclosed. Spec. did not disclose which, if any, compounds selectively inhibit PGHS-2

Undercutting Enzo Biochem, Inc. v. Gen- Probe Inc., 296 F.3d 1316 (Fed. Cir. 2002) (Enzo II) –Deposited sequences meet written description requirement –Subsequences, mixtures, and mutations that hybridize to deposited sequences may meet WD requirement Swing back to Enzo I – very aggressive WD Requirement?

Rochester v Searle, contd Right result, wrong rationale?

Signs of Resistance I Rader, J., in Moba v. Diamond Automation, 325 F.3d 1306, 1322 (Fed. Cir. 2003): –By making written description a free-standing disclosure doctrine, this court produces numerous unintended and deleterious consequences.

Follows a similar criticism in Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956, 976 (Fed. Cir. 2002) (Rader, J., dissenting from denial of rehearing en banc) Signs of Resistance II

Signs of Resistance III University of Rochester v. G.D. Searle & Co., Inc., 375 F.3d 1303, 71 U.S.P.Q.2d 1545 (Fed.Cir.(N.Y.) Jul 02, 2004

Rader, Gajarsa & Linn, dissenting Indeed a brief survey of the literature on this topic, an astounding amount in a few short years, shows 31 articles criticizing the Eli Lilly doctrine, 7 articles defending the doctrine, and 16 neutrally commenting on the state of this evolving case law.5 In its brief requesting en banc reconsideration in Enzo Biochem, the United States issued a call for clarity, which this court has yet to address...

Although this Court has addressed the written description requirement of section 112 on a number of occasions, its decisions have not taken a clear and uniform position regarding the purpose and meaning of the requirement.... A review of the plain text of section 112, and the case law of this Court, reveals at least three different possible tests for an adequate written description.... En banc consideration of the written description provision is appropriate so that the court can provide inventors, the public, and the USPTO with an authoritative interpretation of the provision.

Who is Judge Raders Audience? The Supreme Court? Signs of re-engagement with patent law, 1995 (Markman) (Festo) But of course, only a limited patent diet –Disappointment over Madey v. Duke Univ.

A Normative Interlude Whats wrong with the Written Description requirement? –Diversion of R&D resources...

Described in specificaction Enabled: described or discoverable without undue experimentation

What is the cost of fleshing out the disclosure? What is the value of the enabled but described embodi- ments?

Shouldnt we be encouraging the inventor to invest in the next significant (nonobvious) invention? Rather than fleshing out all the obvious variants of the last invention?

Bring Back Classical Enablement! In re Fisher, 427 F.2d 833 (CCPA 1970) –specification [must be]... Commensurate with the scope of the claims National Recovery Technologies, Inc. v. Magnetic Separation Systems, Inc., 166 F.3d 1190 (Fed Cir 1999): –The scope of the claims must be less than or equal to the scope of the enablement.